NEURANOVA develops portable, rapid neurovascular assessment devices aimed at reducing the time to treatment for stroke patients. Their patented S.T.E.D.I and F.L.A.S.H. devices provide low‑cost, high‑accessibility diagnostics that can be used in a variety of clinical settings to quickly identify vascular blockages. By enabling faster decision‑making, the technology seeks to minimize neuronal loss and improve outcomes in acute stroke care.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Stroke patients often experience critical delays in diagnosis because neurovascular assessment typically requires bulky, expensive equipment and specialized operators, limiting access in many care settings. These delays increase neuronal loss and worsen morbidity and mortality.
Solution
Neuranova addresses this gap with its patented S.T.E.D.I. and F.L.A.S.H. devices, which are compact, rapid, and low‑cost medical tools for neurovascular assessment. The devices can be deployed at the bedside, in ambulances, or in community clinics, enabling clinicians to obtain diagnostic information quickly and initiate treatment sooner. By simplifying the workflow and reducing equipment costs, the technology aims to shorten time‑to‑treatment and improve outcomes for stroke victims.
Target Audience
Primary customers are emergency medical services, hospital emergency departments, stroke centers, and outpatient clinics that require fast, point‑of‑care neurovascular diagnostics.
Features
- Portable, handheld form factor suitable for use in emergency rooms, ambulances, and remote clinics
- Rapid acquisition of neurovascular diagnostic data to support immediate clinical decision‑making
- Patented S.T.E.D.I. and F.L.A.S.H. technologies that combine high‑resolution imaging with streamlined operation
- Low‑cost design that enhances accessibility across diverse healthcare environments
- Battery‑operated with minimal setup, eliminating the need for dedicated imaging suites